spironolactone has been researched along with Arteriosclerosis, Coronary in 11 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study sought to investigate sex differences in outcomes and responses to spironolactone in patients with heart failure with preserved ejection fraction (HFpEF)." | 9.30 | Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. ( Kao, DP; Lindenfeld, J; Merrill, M; Sweitzer, NK, 2019) |
| "Two large trials in heart failure have clearly demonstrated that blocking aldosterone improves mortality and that this benefit occurs over and above standard therapy with angiotensin-converting enzyme (ACE) inhibitors." | 6.43 | Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure. ( Pringle, S; Shah, NC; Struthers, A, 2006) |
| "Spironolactone treatment significantly decreased coronary TRPC expression and dysfunctions in MetS pigs." | 5.46 | Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs. ( Alloosh, M; Beli, E; Chakraborty, S; Chen, X; Grant, MB; Hiett, SC; Li, W; Long, X; Obukhov, AG; Riley, AM; Sturek, M; Temm, CJ; White, FA, 2017) |
| "This study sought to investigate sex differences in outcomes and responses to spironolactone in patients with heart failure with preserved ejection fraction (HFpEF)." | 5.30 | Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. ( Kao, DP; Lindenfeld, J; Merrill, M; Sweitzer, NK, 2019) |
| "Randomized controlled trials demonstrate the efficacy of aldosterone receptor antagonists (spironolactone and eplerenone) as a useful pharmacologic intervention specifically in patients with New York Heart Association (NYHA) class III and IV heart failure, in patients with an ejection fraction <40% after myocardial infarction, and most recently in patients with mildly symptomatic heart failure." | 4.88 | Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications. ( Coplan, NL; Markowitz, M; Messineo, F, 2012) |
| "Two large trials in heart failure have clearly demonstrated that blocking aldosterone improves mortality and that this benefit occurs over and above standard therapy with angiotensin-converting enzyme (ACE) inhibitors." | 2.43 | Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure. ( Pringle, S; Shah, NC; Struthers, A, 2006) |
| "Spironolactone treatment significantly decreased coronary TRPC expression and dysfunctions in MetS pigs." | 1.46 | Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs. ( Alloosh, M; Beli, E; Chakraborty, S; Chen, X; Grant, MB; Hiett, SC; Li, W; Long, X; Obukhov, AG; Riley, AM; Sturek, M; Temm, CJ; White, FA, 2017) |
| "Spironolactone treatment decreased PAI-1 immunoreactivity and reduced in a dose-dependent fashion cardiac and renal damage." | 1.32 | Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. ( Adler, GK; Jonasson, L; Martinez-Vasquez, D; Mukasa, K; Oestreicher, EM; Roubsanthisuk, W; Stone, JR, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, W | 1 |
| Chen, X | 1 |
| Riley, AM | 1 |
| Hiett, SC | 1 |
| Temm, CJ | 1 |
| Beli, E | 1 |
| Long, X | 1 |
| Chakraborty, S | 1 |
| Alloosh, M | 1 |
| White, FA | 1 |
| Grant, MB | 1 |
| Sturek, M | 1 |
| Obukhov, AG | 1 |
| Brown, SM | 1 |
| Meuth, AI | 1 |
| Davis, JW | 1 |
| Rector, RS | 1 |
| Bender, SB | 1 |
| Merrill, M | 1 |
| Sweitzer, NK | 1 |
| Lindenfeld, J | 1 |
| Kao, DP | 1 |
| Kurisu, S | 1 |
| Watanabe, N | 1 |
| Ikenaga, H | 1 |
| Shimonaga, T | 1 |
| Higaki, T | 1 |
| Iwasaki, T | 1 |
| Mitsuba, N | 1 |
| Ishibashi, K | 1 |
| Dohi, Y | 1 |
| Kihara, Y | 1 |
| Bavry, AA | 1 |
| Handberg, EM | 1 |
| Huo, T | 1 |
| Lerman, A | 1 |
| Quyyumi, AA | 1 |
| Shufelt, C | 1 |
| Sharaf, B | 1 |
| Merz, CN | 1 |
| Cooper-DeHoff, RM | 1 |
| Sopko, G | 1 |
| Pepine, CJ | 1 |
| Sudano, I | 1 |
| Naegele, M | 1 |
| Roas, S | 1 |
| Périat, D | 1 |
| Frank, M | 1 |
| Kouroedov, A | 1 |
| Noll, G | 1 |
| Lüscher, TF | 1 |
| Enseleit, F | 1 |
| Ruschitzka, F | 1 |
| Flammer, AJ | 1 |
| Markowitz, M | 1 |
| Messineo, F | 1 |
| Coplan, NL | 1 |
| Oestreicher, EM | 1 |
| Martinez-Vasquez, D | 1 |
| Stone, JR | 1 |
| Jonasson, L | 1 |
| Roubsanthisuk, W | 1 |
| Mukasa, K | 1 |
| Adler, GK | 1 |
| Roongsritong, C | 1 |
| Sutthiwan, P | 1 |
| Bradley, J | 1 |
| Simoni, J | 1 |
| Power, S | 1 |
| Meyerrose, GE | 1 |
| Shah, NC | 1 |
| Pringle, S | 1 |
| Struthers, A | 1 |
| Krakoff, LR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)[NCT00094302] | Phase 3 | 3,445 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| A Double-Blind, Multicenter, Placebo Controlled Study of Aldosterone Blockade (Eplerenone) in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia in the Absence of Significant Epicardial Coronary Artery Disease[NCT00187889] | Phase 4 | 70 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
First incidence of aborted cardiac arrest (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.09 |
| Spironolactone | 0.05 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 4.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 3.1 |
| Spironolactone | 2.8 |
Hospitalization for MI, stroke or the management of heart failure, whichever occurred first (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.2 |
| Spironolactone | 5.5 |
Average post-baseline Chloride, taking into consideration baseline Chloride, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 102.33 |
| Spironolactone | 102.26 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 7.8 |
| Spironolactone | 7.2 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 6.6 |
| Spironolactone | 5.9 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
"Average post-baseline depression, taking into consideration baseline depression, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Patient Health Questionnaire (PHQ) is a 10-item, self-administered instrument for screening, diagnosing, monitoring and measuring the severity of depression. Scores can range from 0-27, in which lower scores reflect better mental health status. The PH-Q was administered at the following study visits: baseline, month 12 and annually thereafter. Valid translations of this questionnaire were only available for subjects enrolled in the United States and Canada." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 5.6 |
| Spironolactone | 5.1 |
First incidence of a deterioration of renal function. The TOPCAT protocol defines deterioration of renal function as occurring if a subject has a serum creatinine value which is at least double the baseline value for that subject, and is also above the upper limit of normal (assumed to be 1.0 mg/dL for females and 1.2 mg/dL for males.) (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 2.2 |
| Spironolactone | 3.2 |
First incidence of atrial fibrillation among subjects without a history of atrial fibrillation at baseline (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.4 |
| Spironolactone | 1.4 |
Average post-baseline GFR, taking into consideration baseline GFR, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mL/min/1.73m2 (Least Squares Mean) |
|---|---|
| Placebo | 67.50 |
| Spironolactone | 65.20 |
First incidence of a hospitalization for any reason (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 20.0 |
| Spironolactone | 18.8 |
First incidence of a hospitalization for the management of heart failure (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 4.6 |
| Spironolactone | 3.8 |
First incidence of myocardial infarction (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.2 |
First incidence of new onset diabetes mellitus among subjects without a history of diabetes mellitus at baseline. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 0.7 |
| Spironolactone | 0.7 |
Average post-baseline Potassium, taking into consideration baseline Potassium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 4.32 |
| Spironolactone | 4.49 |
"Average post-baseline quality of life, taking into consideration baseline quality of life and treatment group.~The McMaster Overall Treatment Evaluation questionnaire is a self-administered 3-item instrument that measures a patient's perception of change in their health-related quality of life since the start of therapy. The questionnaire consists of a single question - Since treatment started, has there been any change in your activity limitation, symptoms and/or feelings related to your heart condition? Scores can range from -7 to +7, and higher scores reflect better health status. The questionnaire was administered at the following study visits: month 4 and month 12. Valid translations of this questionnaire were only available for subjects enrolled in the United States, Canada and Argentina." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.2 |
| Spironolactone | 1.2 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The EuroQOL visual analog scale (EQ5D) is a single-item, self-administered instrument that quantifies current health status. Scores can range from 0-100, in which higher scores reflect better health status. The EQ5D was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 65.9 |
| Spironolactone | 66.4 |
"Average post-baseline quality of life, taking into consideration baseline quality of life, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual.~The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. The KCCQ was administered at the following study visits: baseline, month 4, month 12 and annually thereafter." (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 63.1 |
| Spironolactone | 64.4 |
Average post-baseline serum creatinine, taking into consideration baseline serum creatinine, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 1.11 |
| Spironolactone | 1.17 |
Average post-baseline Sodium, taking into consideration baseline Sodium, treatment group, the time between the post-baseline measures, and the correlation between repeated measures within an individual. (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | mEq/L (Least Squares Mean) |
|---|---|
| Placebo | 140.95 |
| Spironolactone | 140.33 |
First incidence of stroke (NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 1.1 |
| Spironolactone | 1.0 |
(NCT00094302)
Timeframe: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.
| Intervention | Events per 100 person-years (Number) |
|---|---|
| Placebo | 8.3 |
| Spironolactone | 6.8 |
The primary measure was the relative change in coronary diameter to acetylcholinem (ACH) at 16 weeks adjusted for baseline reactivity to acetylcholine. Change in coronary artery diameter after ACH was measured in mm at baseline and 16 weeks. Percent change at 16 weeks - percent change at baseline was the outcome. (NCT00187889)
Timeframe: 16 weeks
| Intervention | % change wk16-%change wk0- unitless (Mean) |
|---|---|
| EPLERINONE | -1.2 |
| PLACEBO | -10.7 |
Coronary flow reserve is a ratio of coronary blood flow velocity before and after adenosine. The outcome measure is the difference between the coronary flow reserve at 16 weeks adjusted for coronary flow reserve at baseline. (NCT00187889)
Timeframe: 16 weeks
| Intervention | difference of ratios (unitless) (Mean) |
|---|---|
| EPLERENONE | -0.4 |
| PLACEBO | -0.4 |
2 reviews available for spironolactone and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications.
Topics: Arrhythmias, Cardiac; Coronary Artery Disease; Diuretics; Heart Failure; Humans; Mineralocorticoid R | 2012 |
Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2006 |
4 trials available for spironolactone and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
Topics: Age Factors; Aged; Aged, 80 and over; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; | 2019 |
Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: an ancillary study of the national heart, lung, and blood institute-sponsored women's ischemia syndrome evaluation.
Topics: Acetylcholine; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2014 |
Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double-Blind, Randomized, Placebo-Controlled Trial.
Topics: Aged; Blood Pressure; Brachial Artery; Coronary Artery Disease; Double-Blind Method; Endothelial Pro | 2016 |
Spironolactone improves diastolic function in the elderly.
Topics: Aged; Aged, 80 and over; Blood Pressure; Coronary Artery Disease; Diastole; Double-Blind Method; Fem | 2005 |
5 other studies available for spironolactone and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs.
Topics: Animals; Calcium Signaling; Cells, Cultured; Coronary Artery Disease; Coronary Vessels; Disease Mode | 2017 |
Mineralocorticoid receptor antagonism reverses diabetes-related coronary vasodilator dysfunction: A unique vascular transcriptomic signature.
Topics: Animals; Arterioles; Coronary Artery Disease; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic | 2018 |
Effects of eplerenone on P-wave signal-averaged electrocardiogram in hypertensive patients with coronary artery disease.
Topics: Aged; Coronary Artery Disease; Electrocardiography; Eplerenone; Female; Humans; Hypertension; Male; | 2014 |
Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury.
Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Coronary Artery Disease; Disease Mode | 2003 |
Is aldosterone a pro-arrhythmic hormone?
Topics: Aldosterone; Arrhythmias, Cardiac; Coronary Artery Disease; Humans; Peptide Fragments; Procollagen; | 2007 |